172 related articles for article (PubMed ID: 10850587)
1. Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy.
Boratyńska M
Ann Transplant; 1999; 4(2):23-8. PubMed ID: 10850587
[TBL] [Abstract][Full Text] [Related]
2. [Role of transforming growth factor beta-1 gene polymorphisms in the development of chronic allograft nephropathy in renal transplant recipients].
Iñigo P; Lario S; Campistol JM; Bescós M; Campos B; Oppenheimer F
Nefrologia; 2003; 23(4):312-20. PubMed ID: 14558330
[TBL] [Abstract][Full Text] [Related]
3. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
[TBL] [Abstract][Full Text] [Related]
4. [TGF-beta1 in allograft and long-term renal function].
Wang PX; Huang XY; Wang AJ; Huang CB; Fan MQ; Zhang YP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):700-3. PubMed ID: 16114562
[TBL] [Abstract][Full Text] [Related]
5. Urinary transforming growth factor-beta1 excretion in renal allograft recipients during the early post-transplantation period.
Goumenos DS; Tsakas S; Karavias D; Savidaki I; Karatzas T; Vlachojannis JG
Ren Fail; 2003 Jul; 25(4):561-8. PubMed ID: 12911160
[TBL] [Abstract][Full Text] [Related]
6. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children.
Melk A; Henne T; Kollmar T; Strehlau J; Latta K; Offner G; Jhangri GS; Ehrich JH; Von Schnakenburg C
Kidney Int; 2003 Jul; 64(1):314-20. PubMed ID: 12787424
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta 1 in renal allograft recipients.
Coupes BM; Newstead CG; Short CD; Brenchley PE
Transplantation; 1994 Jun; 57(12):1727-31. PubMed ID: 8016876
[TBL] [Abstract][Full Text] [Related]
8. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
[TBL] [Abstract][Full Text] [Related]
9. [Influence of transforming growth factor beta1 on long-term renal allograft function].
Wang PX; Fan MQ; Huang CB; Zhnag GF
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1352-5. PubMed ID: 16982454
[TBL] [Abstract][Full Text] [Related]
10. Increased urinary excretion of transforming growth factor-beta(1) in renal transplant recipients during cytomegalovirus infection.
Helanterä I; Teppo AM; Koskinen P; Törnroth T; Grönhagen-Riska C; Lautenschlager I
Transpl Immunol; 2006 Jan; 15(3):217-21. PubMed ID: 16431289
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction.
Pribylova-Hribova P; Kotsch K; Lodererova A; Viklicky O; Vitko S; Volk HD; Lacha J
Kidney Int; 2006 May; 69(10):1872-9. PubMed ID: 16612332
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 in chronic allograft nephropathy following renal transplantation.
Harris S; Coupes BM; Roberts SA; Roberts IS; Short CD; Brenchley PE
J Nephrol; 2007; 20(2):177-85. PubMed ID: 17514622
[TBL] [Abstract][Full Text] [Related]
13. [Association between transforming growth factor beta-1 gene polymorphism and chronic allograft nephropathy].
Li CJ; Yu LX; Xu J; Fu SJ; Deng WF; DU CF; Wang YB
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):535-7. PubMed ID: 17545053
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy.
Viklický O; Matl I; Voska L; Böhmová R; Jaresová M; Lácha J; Lodererová A; Stríz I; Teplan V; Vítko S
Physiol Res; 2003; 52(3):353-60. PubMed ID: 12790768
[TBL] [Abstract][Full Text] [Related]
15. Effect of losartan on slowing progression of chronic allograft nephropathy.
Wang PX; Fan MQ; Huang CB; Feng JY; Xiao Y; Fang ZQ; Zhang YP
Chin Med Sci J; 2005 Dec; 20(4):231-6. PubMed ID: 16422249
[TBL] [Abstract][Full Text] [Related]
16. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients.
Matl I; Viklický O; Voska L; Lodererová A; Vítko S
Transpl Int; 2005 Jun; 18(6):668-71. PubMed ID: 15910291
[TBL] [Abstract][Full Text] [Related]
17. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
18. [Expression of matrix metalloproteinase-9 in renal tissues of rats with chronic allograft nephropathy at early stage and the role thereof].
Zou HQ; Yao J; Wang YX; Wang J; Li D; Wang P
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):981-5. PubMed ID: 16061007
[TBL] [Abstract][Full Text] [Related]
19. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system.
Yamada K; Hatakeyama E; Arita S; Sakamoto K; Kashiwabara H; Hamaguchi K
Clin Exp Nephrol; 2003 Sep; 7(3):238-42. PubMed ID: 14586721
[TBL] [Abstract][Full Text] [Related]
20. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
